Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first cohort in its FDA‑approved Phase I/IIa trial of CMND‑100, an oral MEAI‑based candidate for Alcohol Use Disorder (AUD). Six patients have been enrolled and dosed so far, including two at Johns Hopkins and four at Yale; two additional sites in Israel are activated. The multinational, single‑ and multiple‑dose trial will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption. The release cites a market projection rising from ~$13.2B (2024) to ~ $20B by 2032, highlighting commercial opportunity. Trial registry: NCT05913752.

Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani will be a featured speaker at the “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar on October 29, 2025 at 9:00 AM PT / noon ET.

Dr. Zuloff-Shani will discuss psychedelic research, governance, and therapeutic development—highlighting work on alcohol use disorder, cocaine addiction, and obesity—and share perspectives from her 20+ years in biomedical R&D. The webinar is hosted by the Psychedelic Association of Canada and available via Eventbrite; Clearmind invites investors, researchers, and stakeholders to register and learn about the company’s strategic direction in psychedelic medicine.

Clearmind Medicine (Nasdaq: CMND) appointed Mary-Elizabeth Gifford as Chief of Global Impact effective Oct 27, 2025 to lead US partnerships, governmental and regulatory engagement, and strategic alliances in Washington, D.C. and New York.

Gifford previously held the same role at Psyence BioMed and led public policy at the Center for Mind-Body Medicine. The company noted its 31 granted patents, ongoing clinical trials at Yale, Johns Hopkins and Hadassah, and a Scientific Advisory Board with faculty from Harvard, Yale, and Penn.

Clearmind Medicine (Nasdaq: CMND) enrolled the last patient in the first cohort of its FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Oct 21, 2025. Six patients completed enrollment: two at Johns Hopkins and four at Yale. The multinational, multicenter, single‑ and multiple‑dose study will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol craving and consumption. All participants must want to reduce or stop drinking. Two additional sites in Israel are being activated to support further enrollment. Trial registration: NCT05913752.

Clearmind Medicine (Nasdaq: CMND) announced the publication of a U.S. patent application on October 20, 2025 for a combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines (e.g., PEA) targeting binge behavior disorders.

The application, filed through Clearmind’s collaboration with SciSparc, covers treatment of multiple binge behaviors including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct. Clearmind said this combination leverages MEAI’s neuroplastic effects with PEA’s synergistic pharmacology. The company noted it has filed 13 patents related to the collaboration and cited preclinical data supporting MEAI’s efficacy in mitigating addictive behaviors while preserving normal reward pathways.

Clearmind Medicine (Nasdaq: CMND) held its first Annual Scientific Advisory Board (SAB) meeting, assembling eight leading experts in psychiatry, addiction research, and metabolic disorders. The meeting focused on their lead candidate MEAI (5-Methoxy-2-aminoindane), currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD).

The SAB reviewed MEAI's potential advantages over GLP-1 therapies and its applications for obesity, metabolic syndrome, and veteran mental health. The company's intellectual property portfolio includes 31 granted patents worldwide. The advisory board's insights will guide Clearmind's development strategy for psychedelic-derived therapies.

Clearmind Medicine (Nasdaq: CMND) has secured a securities purchase agreement with institutional investors for convertible promissory notes worth up to $10 million. The initial closing includes notes worth $555,556 for a purchase price of $500,000, with an additional $1.94 million to be issued following SEC registration.

The agreement allows Clearmind to request additional note purchases of up to $2.5 million per quarter, totaling $7.5 million. The notes will be issued at 90% of principal value, carrying a 4% interest rate (14% upon default), with repayment in 10 monthly installments starting 18 months after issuance. The notes are convertible into common shares at a variable price not below $0.20.

Clearmind Medicine (Nasdaq: CMND) announced the publication of an international patent application for a novel combination therapy targeting obesity and metabolic syndrome. The patent, filed under the Patent Cooperation Treaty (PCT), covers the combination of Clearmind's MEAI compound with SciSparc's PEA compound.

The therapy aims to address metabolic syndrome, which affects up to one-third of U.S. adults, combining MEAI's pharmacological profile with PEA's anti-inflammatory and neuroprotective properties. This development is part of a broader collaboration between Clearmind and SciSparc that has generated 13 patent families across multiple jurisdictions including the United States, Europe, and China.

Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD). This approval follows FDA IND clearance and enables patient enrollment at the Jerusalem-based facility.

The multinational, multi-center trial will be conducted at several prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. The study aims to evaluate CMND-100's safety, tolerability, pharmacokinetic profile, and preliminary efficacy in reducing alcohol cravings and consumption in AUD patients.

The trial addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO data.